### Actionable Mapping Report: Resolving Undefined Tier Gene-Drug Associations in Fall and ED Cohorts

#### 1\. Executive Overview of Undefined Tier Gene Mapping

The objective of this report is to resolve "dangling edges" within the Pharmacogenomics (PGx) network topology by mapping genes currently categorized as "Undefined" in the source context to their highly predictive medication features. In visualizations SOURCE\_IMAGE\_1 through SOURCE\_IMAGE\_4, these Undefined genes often appear as peripheral or isolated nodes. By utilizing feature importance rankings and co-metabolization relations derived from specific geriatric cohorts—Emergency Department (ED) and Falls—within the 65-74 and 75-84 age bands, we can integrate these genes into the functional PGx network.The high predictive importance of these Undefined genes in determining adverse outcomes like falls suggests they are strong candidates for CPIC tier reclassification. Establishing these mappings provides a evidence-based framework for clinical actionability in geriatric populations where individual gene-drug associations significantly impact morbidity.

#### 2\. Master Mapping: Undefined Genes to Predictive Medications

The following table serves as the clinical resolution for "Undefined" genes, bridging them to medication features based on ranked feature importance and metabolic proximity.

##### Clinical Actionability Map for Undefined Tier Genes

Undefined Gene,Mapped Medication,Relation Type,Key Evidence (Evidence/Tiers)  
ADD1,FUROSEMIDE,feature\_importance\_drug\_gene,Rank 1 in Falls 65-74 (Imp: 0.1769)  
NEDD4L,HYDROCHLOROTHIAZIDE,feature\_importance\_drug\_gene,Rank 3 in ED 75-84 (Imp: 0.1095)  
PRKCA,HYDROCHLOROTHIAZIDE,feature\_importance\_drug\_gene,Rank 3 in ED 75-84 (Imp: 0.1095)  
YEATS4,HYDROCHLOROTHIAZIDE,feature\_importance\_drug\_gene,Rank 3 in ED 75-84 (Imp: 0.1095)  
CETP,SIMVASTATIN,feature\_importance\_drug\_gene,Rank 3 in Falls 65-74 (Imp: 0.1396)  
LPA,SIMVASTATIN,feature\_importance\_drug\_gene,Rank 3 in Falls 65-74 (Imp: 0.1396)  
ADRA2C,"CARVEDILOL, ATENOLOL",feature\_importance\_drug\_gene,Carvedilol:  Rank 1 in ED 65-74 (Imp: 0.3941);  Atenolol:  Rank 12 in ED 75-84 (Imp: 0.0050)  
GRK4,"CARVEDILOL, ATENOLOL",feature\_importance\_drug\_gene,Carvedilol:  Rank 1 in ED 65-74 (Imp: 0.3941);  Atenolol:  Rank 12 in ED 75-84 (Imp: 0.0050)  
GRK5,"CARVEDILOL, ATENOLOL",feature\_importance\_drug\_gene,Carvedilol:  Rank 1 in ED 65-74 (Imp: 0.3941);  Atenolol:  Rank 12 in ED 75-84 (Imp: 0.0050)  
PTGFR,LATANOPROST,feature\_importance\_drug\_gene,Rank 11 in ED 75-84 (Imp: 0.0105)  
CES1,CLOPIDOGREL,feature\_importance\_drug\_gene,Rank 21 in ED 65-74 (Imp: 0.0078)

#### 3\. Cohort-Specific Feature Importance and Ranks

An analysis of network\_edges.csv data reveals distinct therapeutic clusters where Undefined genes exert maximum predictive influence.

##### The Adrenergic/Beta-Blocker Cluster (ADRA2C, GRK4, GRK5)

This cluster is exceptionally predictive in ED cohorts.  **CARVEDILOL**  emerges as the  **Top Rank 1**  drug in the ED 65-74 cohort (Importance: 0.3941) and remains highly relevant at Rank 5 in the ED 75-84 cohort (Importance: 0.0704). Furthermore, this cluster maps to  **ATENOLOL** , which is identified at  **Rank 12**  in the ED 75-84 cohort (Importance: 0.0050).

##### The Hypertension/Diuretic Cluster (ADD1, NEDD4L, PRKCA, YEATS4)

The mapping here reveals a strong age-band stratification.  **FUROSEMIDE**  attains  **Rank 1**  status in the Falls 65-74 cohort (Importance: 0.1769) and Rank 3 in the Falls 75-84 cohort.  **HYDROCHLOROTHIAZIDE**  is a dominant feature in the ED 75-84 cohort, holding  **Rank 3**  status (Importance: 0.1095).

##### The Lipid/Statin Cluster (CETP, LPA, ABCB1)

**SIMVASTATIN**  serves as the central anchor for this cluster. For the  **ABCB1**  gene, Simvastatin is the  **Rank 3**  drug in Falls 65-74 (Importance: 0.1396) and  **Rank 5**  in Falls 75-84 (Importance: 0.0474). These same ranks (Rank 3 in Falls 65-74 and Rank 5 in Falls 75-84) are also attained for the associations between Simvastatin and the Undefined genes  **CETP**  and  **LPA** .

#### 4\. Temporal Dynamics of Predictive Medications

Temporal sequence analysis from cpic\_time\_to\_event.txt provides the clinical window required for preventive intervention before a fall occurs.

##### Temporal Predictors of Fall Events

* **Predictive Window:**  For medications such as FUROSEMIDE, the predictive window typically manifests  **3-6 weeks**  before a fall event.  
* **Median Timing Gaps:**  
* **Falls 65-74:**  The last consensus drug precedes the fall by a median of  **25.5 days** .  
* **Falls 75-84:**  The last consensus drug precedes the fall by a median of  **37 days** .  
* **Recurring DTW Sequences:**  FUROSEMIDE is a dominant recurring sequence token in the 75-84 age band, often appearing as a target-proximal indicator of fall risk alongside Gabapentin and Prednisone.

#### 5\. Topology Resolution and Pharmacogenomic Context

Mapping Undefined genes effectively resolves the sparse peripheries observed in visualizations SOURCE\_IMAGE\_1 through SOURCE\_IMAGE\_4. These mappings provide "functional bridges" between isolated drug nodes (e.g., Latanoprost or Hydrochlorothiazide) and the highly connected Tier 1 metabolic core of the network.Functional integration is supported by "co\_metabolizes" relations with established Tier 1 genes:

* **Adrenergic Integration:**  The  **ADRA2C/GRK4/GRK5**  cluster co-metabolizes with the Tier 1 gene  **CYP2D6** , as well as the Tier 1 receptors  **ADRB1**  and  **ADRB2** , providing a metabolic link for Carvedilol and Atenolol.  
* **Lipid Integration:**  The Undefined genes  **CETP**  and  **LPA**  (along with Tier 1  **ABCB1** ) co-metabolize with  **SLCO1B1**  and  **CYP3A4**  for Simvastatin metabolism.  
* **Polypharmacy Context:**  Across all 16 cohort strata, the pgx\_num\_drugs feature remains a persistent and dominant factor (maximum combined importance of 1.0). This indicates that while individual gene actionability is being successfully mapped, the total PGx medication burden remains the primary predictive contributor to patient events.

#### 6\. Summary of Actionable Genes by Rank

The following table summarizes the Undefined genes sorted by their highest recorded feature importance rank across the analyzed strata.

##### Highest Feature Importance Ranks for Undefined Genes

Gene Symbol,Highest Rank Attained,Target Cohort/Age Band  
ADRA2C,Rank 1,ED 65-74  
GRK4,Rank 1,ED 65-74  
GRK5,Rank 1,ED 65-74  
ADD1,Rank 1,Falls 65-74  
NEDD4L,Rank 3,ED 75-84  
PRKCA,Rank 3,ED 75-84  
YEATS4,Rank 3,ED 75-84  
CETP,Rank 3,Falls 65-74  
LPA,Rank 3,Falls 65-74  
PTGFR,Rank 11,ED 75-84  
CES1,Rank 21,ED 65-74  
